NASDAQ NMS - GLOBAL MARKET · INCY
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Incyte Corp

Incyte Corp

Biotechnology
$123.50
Card
Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factorsMethodology
INCY
Incyte Corp
Mon Aug 17 · last completed session · Pre-market · regular session opens 9:30 ET
STRONG

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

80/ 100
Veridion Score
STRONG · HIGH confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Mon Aug 17 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Score not reportedVeridion does not publish a score-history trend for INCY until the ticker has a real scored snapshot. No trend is implied for this page.Review methodology
AI Analysis
Sovereign

Why is INCY moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading INCY catalysts
About Incyte Corp
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Listed since
1993
Employees
3K
Country
US

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$123.50
Last session
Day high
$123.50
Last session
Day low
$123.50
Last session
Previous close
$123.50
52W high
$129.93
-4.95% from high
52W low
$81.66
87% of range
Market cap
$24.4B
P/E
14.65×
EPS
$8.43
Beta
-0.30
Shares out
202.7M
Avg volume
1.8M
VWAP
$123.50
Last session
Price history computed in-house
1W
+2.01%
1M
+5.33%
3M
+27.21%
1Y
+45.43%
YTD
+25.04%
SMA 50 $114.29 · above
SMA 200 $103.01 · above
52W position 87%

INCY overview

Veridion Score
Not reported
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around INCY.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading INCY Form 4 filings
Public disclosures

Congress activity in INCY

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for INCY in the cached public ledger.

Federal contracts

INCY contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for INCY in this window.
Lobbying spend

INCY lobbying filings, year to date.

Registered lobbying filings matched to Incyte Corp.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for INCY in this window.
Loading news for INCY
Analyst ratings
Sovereign unlock shows live analyst consensus for INCY.
Options
Sovereign unlock shows live options positioning for INCY.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.